Venus Remedies Q2 FY27 Results (NSE: VENUSREM)

· Analysis by Alpha Inflection

Signal: Margin expansion

Venus Remedies Q2 FY27 key financials
MetricValueYoYQoQ
Revenue₹218.78 Cr+13.5%+22.3%
EBIT₹43.01 Cr+31.7%
Net profit₹25.65 Cr+27.4%
EPS₹19.19+27.4%
EBIT margin19.6%

P&L walk

Consolidated revenue rose to ₹218.78 Cr (+13.5% YoY, +22.3% QoQ); lower raw-material intensity lifted gross margin to about 51.4%, EBITDA increased to ₹43.01 Cr (+31.7% YoY), and PAT reached ₹25.65 Cr (+27.4% YoY).

View original filing

Research and educational content only. Not investment advice.